Tumor Clearly Removed, but Post-Op HPV Test Still Positive: Is It a Sign of Recurrence?

Understanding Positive HPV Results After Cancer Surgery

For patients who have undergone surgery for HPV-related cancers, a common and deeply unsettling scenario unfolds during follow-up visits. The surgeon confirms the tumor was removed with clear margins, yet a subsequent HPV test returns positive. This immediately raises a terrifying question: does a positive HPV test after surgery mean the cancer is coming back? Experts from Fudan University Shanghai Cancer Center clarify that the answer is not always straightforward and is often not a direct signal of recurrence.

Human papillomavirus (HPV) is a primary causative agent for several cancers, most notably cervical cancer, but also a significant proportion of oropharyngeal, anal, penile, vaginal, and vulvar cancers. The role of HPV testing in screening and follow-up is well-established, but interpreting results after definitive treatment requires a nuanced understanding of viral biology and surgical outcomes.

Why Does the Virus Persist After Tumor Resection?

The fundamental reason a post-operative HPV test can remain positive lies in the nature of the virus itself. When a surgeon performs a radical resection, the goal is to remove the macroscopic tumor and a margin of healthy tissue. This addresses the localized disease. However, HPV is a multi-site, field-defining infection. The virus can exist in a latent or active state in surrounding mucosal areas that appear completely normal and are not excised during surgery.

Professor Wu Xiaohua, a leading gynecologic oncologist at Fudan University Shanghai Cancer Center, explains that a positive HPV test after surgery often reflects a persistent or new infection in the remaining tissue, rather than a regrowth of the original tumor. “Think of the surgical field as a forest where we removed a diseased tree,” she analogizes. “The soil and surrounding trees may still harbor the pathogen that caused the disease. A positive test tells us the ‘soil’ condition hasn’t cleared, not necessarily that the removed tree is growing back.”

Distinguishing Between Residual Infection and True Recurrence

Clinicians rely on a combination of tools to differentiate a benign persistent infection from a true recurrence. An HPV DNA test alone is insufficient. The critical distinction comes from correlating the HPV result with cytology (such as a Pap smear for cervical cancer patients), high-resolution imaging, and a thorough physical examination. A positive HPV test with completely normal cytology and no visible lesions on imaging is typically managed with closer surveillance rather than immediate intervention.

Research from the cancer center indicates that the clearance rate of HPV after surgery can be slow, sometimes taking 12 to 24 months for the immune system to suppress the virus to undetectable levels. The persistence of the same high-risk HPV genotype that caused the original cancer warrants more vigilance than a new infection with a different genotype. However, even same-type persistence does not equal recurrence; it is a risk factor that requires careful monitoring.

The Role of Immune Clearance and Follow-Up Protocols

The body’s immune system is the ultimate factor in clearing HPV. Surgical removal of the tumor burden can actually aid this process by reducing the viral load. Standardized follow-up protocols at major Chinese cancer centers now integrate HPV testing as a surveillance biomarker, but always in conjunction with other modalities. For cervical cancer patients, this means co-testing with cytology. For oropharyngeal cancer patients, it may involve regular endoscopic examinations and imaging.

Experts emphasize that patients should not interpret a positive HPV result in isolation as a treatment failure. The psychological burden of “viral positivity” can be immense, leading to anxiety and depression. Clear communication from the oncology team about the meaning of these results is a crucial component of survivorship care. In many cases, the immune system will eventually clear the virus without any additional treatment.

What This Means for International Patients

For international patients considering post-operative follow-up or seeking second opinions on HPV-related cancers, this insight is particularly valuable. The interpretation of post-treatment biomarkers can vary significantly between institutions. Major oncology centers in China, such as Fudan University Shanghai Cancer Center, follow rigorous, integrated surveillance protocols that combine molecular testing with advanced imaging to avoid overtreatment based on a single lab value. Patients traveling for care should ensure their follow-up plan includes a clear strategy for interpreting HPV results in the context of their entire clinical picture, not as an isolated trigger for alarm. This nuanced approach reflects the depth of subspecialty expertise available in China’s top-tier cancer hospitals, where managing the long-term survivorship journey is prioritized alongside initial surgical success.

Reviewed by ToChinaMed. Published: 2025-05-20. This article is based on publicly available medical news and is not a substitute for professional medical advice.

ToChinaMed helps international patients find reliable medical treatment in China.

Source: Fudan University Shanghai Cancer Center via Shanghai Observer